Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from its open-label Phase 2a trial.
Where Today's News Shapes Tomorrow
March 3, 2026
Headlines
